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Abstract 
Importance: 
There are reports that a sex disparity exists in outcomes in patients with COVID-
19, with men having more severe cases and higher mortality than women. 
Objective: 
To conduct a meta-analysis of current studies that examined sex differences in 
severity and mortality in patients with COVID-19, and identify potential mechanisms 
underpinning these differences.  
Methods:  
We performed a systematic review to collate data from observational studies 
examining associations of sex differences with clinical outcomes of COVID-19. 
PubMed, Web of Science and four preprint servers were searched for relevant studies. 
Data were extracted and analyzed using meta-analysis where possible, with summary 
data presented otherwise. Publicly available bulk RNA sequencing (RNA-seq), 
single-cell RNA sequencing (scRNA-seq), and chromatin immunoprecipitation 
sequencing (ChIP-seq) data were analyzed to explore the potential mechanisms 
underlying the observed association. 
Results:  
39 studies met inclusion criteria, representing 77932 patients, of which 41510 
(53.3%) were males. Men were at a markedly increased risk of developing severe 
cases compared with women (OR = 1.63; 95% Cl = 1.28-2.06). Furthermore, the 
pooled odds ratio (OR) of mortality for male group compared with the female group 
indicated significant higher mortality rate for male (OR = 1.71; 95% CI = 1.51-1.93). 
Subgroup analyses suggested that in patients with average age > 50 yr, the male had 
significantly higher severity rate than female (OR = 1.94; 95% Cl = 1.16-3.26). 
However, in patients with average age < 50 yr, the male group only exhibited a 
marginally increased severity rate compared with the female group (OR = 1.45; 95% 
Cl = 1.07-1.96). Data from scRNA-seq suggest that men have a higher amount of 
ACE2-expressing pulmonary alveolar type II cells than women. Sex-based 
immunological differences exist, with cytokines associated with cytokine release 
syndrome preferentially expressed in men, and those associated with defense and 
recovery from viral infection preferentially expressed in women. ScRNA-seq data of 
the prostate and testis revealed that these two organs might be potential targets for 
SARS-CoV-2 infection in the male population. The expression of androgen receptor 
(AR) is positively correlated with ACE2, and there is evidence that AR may directly 
regulate the expression of ACE2.  
Conclusions:  
This meta-analysis detected an increased severity and mortality rate in the male 
populations with COVID-19, which might be attributable to the sex-based differences 
in cellular compositions and immunological microenvironments of the lung. The host 
cell receptor ACE2 is likely regulated by AR signaling pathway, which is identified as 
a potential target for prevention and treatment of SARS-Cov-2 infections in men. 
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Introduction 
Coronavirus disease 2019 (COVID-19), ascribed to the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), is an emerging outbreak globally since 
December 2019. The management of COVID-19 has become a current emergency 
public health event, which has attracted increasing attention. Early recognition, testing 
and isolation are the effective response to curb transmissions.1,2 Health security 
capacities improving, global collaboration in relation to COVID-19 and current travel 
restrictions are necessary for global epidemic control.3,4 Around 6.4-24.9% of patients 
infected with SARS-CoV-2 may progress to severe and even fatal acute respiratory 
distress syndrome (ARDS), 5-26.1% of patients need treatment in the intensive care 
unit (ICU), and the fatality rate of patients can reach 1.4-7.2%.5-8 Older age, higher 
Sequential Organ Failure Assessment (SOFA) score, chronic comorbidities were the 
risk factors associated with the patients of the 2019-nCoV infection9,10. However, 
whether the sex difference is related to the risk factors for infection, severity, and 
mortality of COVID-19 is still lacking a comprehensive analysis based on the 
integration of new studies.11 
Although some cases report support for sex differences to be associated with the 
onset and prognosis of COVID-19 pneumonia,12 some studies do not support this 
observation. The Chinese Center for Disease Control and Prevention reports on 44672 
confirmed cases showing that sex differences may be a risk factor for mortality, but 
there is no sex differences in morbidity.7 Even more confirmed cases of female than 
male in South Korea are reported by the Korean Society of Infectious Diseases.13 
Therefore, a meta-analysis was performed to reveal the correlation between sex 
differences and the prevalence, severity and mortality of COVID-19 pneumonia. 
ACE2 as a receptor of SARS-CoV and spike protein can be primed by TMPRSS2 are 
exploited to entry into target cells, which play an vital role in coronavirus pneumonia 
infection.14We also performed an integrated bioinformatic analysis, leveraging data 
from bulk microarray, bulk RNA sequencing (RNA-seq), single-cell tRNA 
sequencing (scRNA-seq), and chromatin immunoprecipitation sequencing (ChIP-seq) 
to provide valuable clues of possible underlying mechanism. 
Materials and Methods 
Systematic review and Meta-analysis 
Search Strategy and Selection Criteria 
Two of the investigators (W.X. and W.J.) independently retrieved relevant 
literature from the databases including PubMed, Web of Science, bioRxiv and 
MedRxiv preprint servers from inception to March 19, 2020. We searched studies 
with no language restrictions to analyze the association between sex difference with 
prevalence, severity and mortality of the patients with the 2019-nCoV infection. 
Keywords and relative variant search terms were utilized as follows: SARS-CoV-2 
and COVID-19. These terms were combined with "AND" or "OR". We first reviewed 
the titles and abstracts of the retrieved citations (excluding conference abstracts and 
critical articles), and then evaluated the eligibility for inclusion of the full text that 
was deemed pertinent. 
We searched the literature on cases of the 2019-nCoV infection reported in 
different countries since December 2019. We excluded studies that may overlap based 
on the relative information reported in the studies, such as the time of patient data 
collection, hospital units and departments. We uniformity defined ICU patients, 
ARDS patients, severe patients and critical patients as severe group in our study. 
Inclusion criteria should comply with the following:1) observational studies that 
involved patients with the 2019-nCoV infection had a detailed description of the sex 
ratio, number of severe or dead patients; 2) studies with the most reported cases if 
data overlap with another document. Exclusion Criteria: 1) studies that did not 
provide available full text; 2) studies not reported separately for gender or no desired 
data; 3) data overlapping. 
Data Extraction and Quality Assessment 
Two investigators extracted independently the data from eligible studies. Any 
discrepancy was resolved by consensus. The following information was abstracted: 
the last name of the first author; date of manuscript acceptance or publication; date of 
patient collection; total patients in the study; number of male participants, number of 
female participants; number of severe cases; number of severe male cases; number of 
severe female cases; number of cases with comorbidities; number of deaths; number 
of male deaths; number of female deaths and smoking history. 
We evaluated potential sources of bias in included studies using the appraisal tool 
to assess the quality of cross-sectional studies (AXIS) (Supplementary Table S1) .15  
Pooled Analysis  
The data of individual studies were summarized. We attempted to perform 
analysis of sex difference predisposition of incidence, severity, and mortality in 
patients COVID-19. Subgroup analyses of sex differences predisposition of severity 
were also carried out according to the average age of patients in included studies. 
Meta-analysis was undertaken with Stata v12.0 (Stata Corporation, College Station, 
TX, USA) software, the results of which were presented in forest plots. Heterogeneity 
among studies were estimated using fixed-effects and random-effects models, which 
was reported using the Cochrane’s Q-test 16 and the inconsistency index value (I²) 17. 
Funnel plots and Egger test were used to assess for publication bias and small study 
effects. All hypothesis tests were two-tailed. P < 0.05 was considered statistically 
significant. 
For any outcome measurement that is otherwise not meta-analyzable, we 
presented an albatross plot,18 which is a novel graphical tool for presenting results 
from studies, allowing an approximation of underlying effect sizes and the potential 
identification of heterogeneity sources across studies. The albatross plots were 
constructed using Stata v14.0 (Stata Corporation, College Station, TX, USA). 
Bioinformatic Analyses 
Single-cell RNA Sequencing Analysis Pipeline 
Single-cell RNA Sequencing (scRNA-seq) data analysis was performed by 
NovelBio Bio-Pharm Technology Co.,Ltd. with NovelBrain Cloud Analysis Platform. 
We applied fastp 19 with default parameter filtering the adaptor sequence and removed 
the low quality reads to achieve the clean data based on the GSO datasets (Normal 
Prostate: GSE117403 and Normal Lung tissue: GSE122960). We downloaded the 
aggregated matrix. Cells contained over 200 expressed genes and mitochondria UMI 
rate below 20% passed the cell quality filtering and mitochondria genes were removed 
in the expression table. 
Seurat package (version: 2.3.4, https://satijalab.org/seurat/) was used for cell 
normalization and regression based on the expression table according to the UMI 
counts of each sample and percent of mitochondria rate to obtain the scaled data. PCA 
was constructed based on the scaled data with top2000 high variable genes and top 10 
principals of 20 PCs were used for tSNE construction and UMAP construction. 
Utilizing graph-based cluster method, we acquired the unsupervised cell cluster result 
based the PCA top 10 principal and we calculated the marker genes by 
FindAllMarkers function with wilcox rank sum test algorithm under following 
criteria:1. lnFC > 0.25; 2. P value<0.05; 3. min.pct>0.1. 
 The corresponding websites for the datasets, if available, were used for 
downloading figures for visualization of scRNA-seq data of normal human tissues of 
the prostate (https://strandlab.net/) and the testis 
(https://humantestisatlas.shinyapps.io/humantestisatlas1/). 
Cell Communication Analysis.  
To enable a systematic analysis of cell–cell communication molecules, we 
applied cell communication analysis based on the CellPhoneDB,20,21 a public 
repository of ligands, receptors and their interactions. Membrane, secreted and 
peripheral proteins of the cluster of different time point was annotated. Significant 
mean and Cell Communication significance (p value<0.05) was calculated based on 
the interaction and the normalized cell matrix achieved by Seurat Normalization. 
Differential Gene Expression Analysis 
To identify differentially expressed genes among samples, the function 
FindMarkers with wilcox rank sum test algorithm was used under following criteria:1. 
lnFC > 0.25; 2. P value<0.05; 3. min.pct>0.1. Volcano plot was constructed by the R 
package “ggplot2”. 
Co-regulation Network Analysis 
To discover the gene co-regulation network, find gene modules function of 
monocle3 22 was used with the default parameters.   
GO analysis 
Gene ontology (GO) analysis was performed to elucidate the biological functions 
or processes of the differentially expressed gene in the experiment.23 GO annotations 
were downloaded from NCBI (http://www.ncbi.nlm.nih.gov/), UniProt 
(http://www.uniprot.org/) and the Gene Ontology website 
(http://www.geneontology.org/). Fisher’s exact test was utilized to identify the 
significant GO categories and q-values were calculated for false discovery rate 
control.  
Pathway Analysis 
KEGG database was used to figure out the significant pathways enriched. 
Fisher’s exact test was utilized to select the significant pathway, and the threshold of 
significance was defined by FDR cutoff values.24  
Bulk Microarray/RNA-seq Data Analysis 
Microarray data available from public repositories were accessed from GSE5901 
and GSE 56188 using the R package “GEOquery”. Gene expression analysis and 
visualization were performed using custom R codes. Correlation between genes were 
analyzed using the publicly available TCGA datasets at the TIMER 2.0 website 
(http://timer.cistrome.org/).25  
ChIP-seq analysis 
ChIP-seq data from the ENCODE project26 were analyzed using the WashU 
EpiGenome Browser.27 Human tissue samples or standard cell lines with both AR 
ChIP-seq data and histone mark ChIP-seq data available were selected.  
 
Results 
Study Selection and Characteristics 
We recorded the selection process and completed a PRISMA flow diagram 
(Figure 1). From a total of 1561 records identified and screened by abstract and title, 
108 articles were selected for full-text assessment. Among these, 69 were excluded 
due to lack of gender distinction or overlapping data. Thirty-nine studies, published 
between February 7, 2020 and March 17, 2020, were finally filtered for qualitative 
analysis and quantitative meta-analysis , thirty-four from China and five from other 
countries (Table 1), 5-8,10,13,28-60including a total of 77932 patients with an approximate 
average age of 61.04. Most studies were retrospective study, and ten were descriptive 
case series. The comprehensive characteristics of patients subsumed are displayed in 
Table 1, including gender ratio, severe cases, smoking history, death cases and 
comorbidity information. Three variables were analyzed for the meta-analysis in our 
systematic review.  
Meta-analysis results 
The comprehensive results of our meta-analysis are presented in Figure 2, Table 2, 
Table3 and Table 4. Thirty-nine studies involving 77932 patients were assessed in the 
comparison of the sex differences in patient composition. Part of the reported cases 
are concentrated in Wuhan, China, but from different hospitals. Overall, male 
accounted for 53.3% of all patients and female accounted for 46.7% (41510, 36408 
respectively). Among the patients included, the number of males was higher than that 
of females (39 studies; 77932 patients; Odds = 1.12), especially in the Chinese 
population (34 studies; 50488 patients; Odds = 1.13). Because the sex-specific 
numbers of the general population in the investigated areas are typically not provided, 
a meta-analysis for sex-specific incidence or morbidity is not feasible. We therefore 
provided an albatross plot for visualization of the comparison of the male proportion 
in each study with 0.5 (Figure 2A). It can be observed from the albatross plot that 
studies with large sample sizes and low p values tend to report a male proportion over 
0.5. Twenty-one studies (3905 patients) reported the severe cases according to the 
setting standards mentioned above. Regarding the severe case rate (Figure 2B), the 
male group exhibited a prominently increased severity rate compared with the female 
group (21 studies; 3905 patients; OR = 1.63; 95% Cl = 1.28-2.06, P=0.000). Subgroup 
meta-analysis suggested that in patients with average age > 50 yr, the male had 
significantly higher severity rate than female (OR = 1.94; 95% Cl = 1.16-3.26, 
P=0.000). However, in patients with average age < 50 yr, the male group only 
exhibited a marginally increased severity rate compared with the female group (OR = 
1.45; 95% Cl = 1.07-1.96, P=0.006, Figure 2C). A total of 8 studies included 
information of smoking history with available information about percentage of severe 
cases.8,10,39,43,44,55,58,60 With the percentage of positive smoking history ranged from 
5.6% to 23.3%. A total of only 252 cases with smoking history were reported against 
the study outcome. We consider it would be inappropriate to pool the results for 
stratified analysis based on the limited cases. In the 39 studies mentioned above, a 
total of 8 studies (50936 patients) provided mortality information. The pooled 
estimate of OR of mortality for male group compared with the female group indicated 
significant survival risk for male (8 studies; 49869 patients; OR = 1.71; 95% CI = 
1.51-1.93, P=0.000) (Figure 2D).   
Heterogeneity, Publication bias and Sensitivity analysis 
Regarding the severity and mortality, moderate heterogeneity was observed 
(I2=40.9%, I2=0.0% respectively). However, heterogeneity increased when analysis of 
patients’ sex composition was conducted (overall I2=95.8%, China subgroup 
I2=57.2%). Supplementary Figure S1A and S1B indicate that no significant 
publication bias for the gender composition and severe rate analysis was observed, 
which was confirmed by Eggers test (Table S2) (p=0.777, P = 0.055, respectively). In 
addition, there was no published bias for mortality analysis (Supplementary Figure 
S1C) (Egger’s test: P = 0.376). The influence of each study on the combined results 
was detected by sensitivity analysis. Table S3 and Table S4 show that no individual 
study significantly affected the combined OR. 
Identification of Sex-Based Differential Gene Expression  
To explore the molecular aspects of the potential sex-based physiological and 
immunological differences, we first analyzed a published human lung tissue scRNA-
seq datasets. After data processing and quality control procedures, transcriptomic 
profiles for 43358 cells from human lung samples were acquired (Figure 3A). 
We identified 19 clusters using graph-based clustering method. Based on marker 
gene expression, a total of 10 cell types were identified, including pulmonary alveolar 
type I (AT1) cells, AT2 cells, ciliated & goblet cells, endothelial cells, Fibroblasts, 
Macrophages, monocytes, plasma cells, and T cells. Comparison of the abundance of 
different cell types in male and female lung tissues was presented in Figure 3B. Most 
cell fractions do not differ greatly between tissues of male and female origins, except 
for plasma cells which are preferably enriched in female samples. Given the 
comparable percentages of total AT2 cells, men have a significantly higher percentage 
of ACE2-expressing AT2 cells. Feature plot also revealed a higher level of ACE2 
expression in male lung tissue, especially in AT2 cells (Figure 3C). We performed a 
co-expression network analysis in the cells from male samples and discovered that, 
among others, androgen receptor (AR) exhibited a co-expression pattern with ACE2 
(Figure 3D). 
To further elucidate the role of sex-based impact on ACE2 expression and 
downstream effects, differential expression analysis was performed between ACE-
expressing cells of male and female origins (Figure 4A). We discovered that the 
down-regulated genes in the male populations were enriched in pathways related to 
viral infections and immune response (Figure 4B). Intercellular communication 
analysis using CellPhoneDB revealed an active state of ACE-expressing AT2 cells, 
with ACE2 functioning both as a receptor and a ligand (Supplementary Figure S2). As 
cytokines are essential regulators of infection and immune response, we focused on 
the differential sex-based differential expression patterns on cytokines (Figure 4C). 
We discovered that IL6ST, a receptor of IL6, is expressed both in male and female 
population, with an average expression higher in male populations. Pro-inflammatory 
cytokines and chemokines, including CCL14, CCL23, IL7, IL16, and IL18, are also 
preferentially expressed in men, underlying the higher susceptibility of men 
developing cytokine release syndrome. TNFSF13B, which has been shown to be 
associated with the progression of chronic obstructive pulmonary disease (COPD) and 
pneumonia, is highly expressed in the monocyte-macrophage lineages of men. In 
contrast, cytokines with reported protective effects against viral infections, including 
CCL2, CCL3, and CCL4, are highly expressed in women.  
In addition, we looked at scRNA-seq data of tissues from normal, male-specific 
organs including prostate and testis (Supplementary Figure S3-4). Two independent 
scRNA-seq datasets of the healthy human prostate tissues demonstrated that ACE2 is 
expressed in most prostate epithelial cell clusters, pericytes, and fibroblasts. scRNA-
seq datasets of the testis revealed that ACE2 is preferentially expressed in Leydig and 
Sertoli cells. These data have provided evidence that prostate and testis could be 
potential targets for SARS-CoV-2 infection in men. 
Androgen receptor positively regulates ACE2 and 
TMPRSS2 
Previous reports have highlighted the role of ACE2 and TMPRSS2 as 
dependencies for SARS-CoV-2 cell entry.14 The role of AR acting as a transcription 
factor to activate the expression of TMPRSS2 has already been studied extensively in 
the context of various malignancies. We hypothesized that AR could also directly 
regulate ACE2 expression. At the single-cell level, we found a positive correlation 
between TMPRSS2 and ACE2 expression (Figure 5A, Pearson correlation coefficient 
r = 0.713). To verify this expression pattern across the spectrum of human tissues, we 
tested the correlation of expression level of AR and ACE2/TMPRSS2 in the TCGA 
PANCAN dataset (Figure 5B). We found that expression of ACE2 and TMPRSS2 is 
positively correlated with AR, irrespective of tissue types. We then utilized publicly 
available microarray datasets to investigate the impact of chemical or surgical 
castration, which lowers the level of androgens, on the expression level of these two 
genes. Unsurprisingly, both in vitro and in vivo studies (Figure 5C-D) demonstrated 
that castration leads to the decline of ACE2 and TMPRSS2, which could be reversed 
through androgen supplementation. To understand the mechanism underpinning the 
positive correlation between AR and ACE2, we analyzed publicly available ChIP-seq 
datasets and found that, around 4000 bp upstream of ACE2 transcription start site 
(TSS), there is overlap between AR ChIP-seq peaks and H3K4me1/H3K27ac ChIP-
seq peaks (Supplementary Figure S5-6), indicating that AR likely binds to the 
enhancer regions and promotes the expression of ACE2. 
 
Discussion 
In recent months, SARS-CoV-2 quickly becomes a serious public health issue 
worldwide. 59-62 COVID-19 is a species of coronavirus family, which is homologous 
with the SARS virus and MERS virus, causing diseases ranging from common cold to 
severe pneumonia. 63,64However, the knowledge of the COVID-19 remains poorly 
understood. Altogether, the disease could be divided into four clinical types, including 
mild, moderate, severe and critical pneumonia. 7 Recently, the epidemiology and 
clinical features of patients with COVID-19 have been widely reported. 60,61,65,66 
However, few studies have focused on the sex differences in the prevalence, severity 
and death of COVID-19. 
This study is the first meta-analysis to appraise the role of gender in the incidence 
rate, morbidity and mortality of SARS-CoV-2 infection. Our pooled results 
demonstrated that gender played a prone role in COVID-19 infection. Concretely, 
male patients exhibited higher morbidity, incidence of severe disease and mortality 
compared with female patients. Of the 77992 patients with COVID-19 included in our 
study, 53.3% were men, indicating that men were more likely to be infected with sars-
cov-2 than women. Unanimously, in the analysis of 1755 SARS cases by Karlberg et 
al. 67  the mortality rate of men was significantly higher than that of women (21.9% 
vs 13.2%, P < 0.0001). Leung et al, 68 showed that in SARS patients, men were more 
likely to experience adverse events. It is worth noting that there is no clear evidence 
of sex differences in the prognosis of influenza. 69-71 The sex differences of morbidity 
and prognosis is believed as a characteristic of coronavirus infection. In addition, we 
discovered that male patients with age > 50 yr were associated with a greater risk of 
progressing to severe cases or ICU cases. Interestingly, the epidemiological data from 
the 2002-2003 SARS epidemic and recent MERS also indicated that there might be 
sex and age-dependent differences in disease outcomes. According to the 
epidemiology analysis of SARS in the 2003 Hong Kong epidemic, both increasing 
age and male sex were associated with a greater risk for death.68 Channappanavar et 
al. infected mice with SARS-CoV and demonstrated that male mice were more 
susceptible to SARS-CoV infection compared to age matched females. Furthermore, 
the degree of sex-bias to SARS-CoV infection in middle-aged mice was more 
pronounced compared to young mice.72 Together, these data suggested that older male 
patients with COVID-19 should get more attention and prepared for ICU treatment 
when they were still mild cases.  
The specific mechanism of sex differences is not clear. Some studies have shown 
that different outcomes between males and females may pertain to the possibility that 
estrogen protects women from worse clinical outcomes during SARS-CoV 
infection.67,73 In a risk factor analysis of patients with COVID-19, smoking history 
was identified as a risk factor for disease progression.43 It was illustrated that the 
expression of ACE2 is significantly higher in the lungs of smokers, which might be 
the reason for higher percentage of sever cases in smokers. Notably, the smoking rate 
of men is typically much higher than that of women.12 This seems to explain the 
results theoretically, however, there was only a small proportion of cases with 
smoking history and thus the influence of smoking on sexual differences seems to be 
weak. Another possible explanation is the different levels of ACE2 expression. 
Current results show that SARS-CoV-2 enter into cells through ACE2, and the 
receptor binding domain of SARS-CoV-2 S and SARS-CoV  possess homologous 
affinity to ACE2. 74 Research has shown that Compared with SARS-CoV, the 
receptor binding domain of SARS-CoV-2 has a higher binding force to ACE2 than 
that of SARS-CoV-2.75Anterior studies have reported that the high expression of 
ACE2 receptor in idiosyncratic organs of SARS patients pertains to the corresponding 
specific organ failure.76,77 It should be noted that the ACE2 gene is pitched on the X 
chromosome. Studies have shown that men had higher levels of circulating ACE2 
than women and patients with diabetes or cardiovascular disease.78 Therefore, due to 
the high expression of ACE2, male patients may be more likely to develop severe 
symptoms and die of SARS-CoV-2. In addition to that, spike protein promotes the 
attachment and entry of coronavirus into target cells by binding to its cellular 
receptor.79 Recent studies have confirmed that in COVID-19, SARS-CoV-2 also relies 
on the priming of spike protein by TMPRSS2 to enter target cells. Inhibitors of 
TMPRSS2, as a clinical option, can block virus entry.14 However, the mechanisms 
need further elucidation. 
In our study, single-cell transcriptomic profiling of human lung tissue samples 
revealed that ACE2 expression is higher in male lung tissue than in female, and that 
AR is co-expressed with ACE2/TMPRSS2. It is worth mentioning that androgen 
expression is significantly higher in men than women. This is consistent with our 
findings that COVID-19 has a higher incidence severity and mortality in men. We 
speculate that AR may be one of the important factors causing gender differences in 
COVID-19. Our further integrated bioinformatic analysis revealed that in LNCaP 
prostate cancer cell line, the expression of ACE2 and TMPRSS2 decreased 
significantly after treatment with the AR inhibitor bicalutamide. Similarly, in the 
prostate of castrated mice, the expression of ACE2 and TMPRSS2 decreased 
significantly, and their expression was up-regulated after supplementation with 
androgen. These evidences suggest that anti-AR may be a new strategy for treating 
males with SARS-CoV-2 infection. However, further research is needed to confirm 
this speculation. 
A great quantity of patients with severe COVID-19 infection have experienced 
cytokine release syndromes, or “cytokine storms”.60 Previous cases of infectious 
diseases such as SARS, Middle East respiratory syndrome and Ebola virus infections 
have also demonstrated that cytokine storms can trigger the immune system to attack 
the body violently, which is a momentous cause of acute respiratory distress 
syndrome and multiple organ failure.80-82 A previous study demonstrated that there 
was a positive correlation between the severity of pneumonia and the cytokine storm 
and inflammatory response caused by intravascular virus.83,84 IL-6 is the main 
proinflammatory factor causing cytokine storm, which can significantly damage organ 
function, as well as IL-7, IL-16 and IL-18.45,85,86 Our study observed that the 
expression levels of Il-6ST, IL-7, IL-16 and IL-18 in male were significantly higher 
than that in female. These findings and observations may help to explain why the risk 
of severe events in male is strikingly higher than in female. 
Our data revealed that CCL14, CCL21, and CCL23 (important pro-inflammatory 
factors) have increased expression in the lungs of male patients with COVID-19, 
which may promote COVID-19-related cytokine storms. In flu disease, type I 
interferon-mediated production of the CCL2 recruits inflammatory dendritic cells 
(IDCs) to the tracheal epithelium, which is conducive to virus control.87 Previous 
studies have shown that CCL3, CCL4 can inhibit HIV-1 from entering CD4 T cells 
and play a protective role.88 CXCL16, mainly located in the respiratory epithelium, is 
a ligand for CXCR6 playing an important role in homeostasis of Resident memory T 
cells in the respiratory tract.89 In our study, the expressions of CCL2, CCL3, CCL4, 
and CXCL16 were lower in male patients than female patients, which may aggravate 
the condition of male COVID-19 patients to a certain extent. BAFF (gene name 
Tnfsf13b) is closely related to B-cell activation and adaptive humoral immune 
response. BAFF is elevated in lung tissue of COPD patients and can cause lung 
inflammation and injury. 90 Therefore, our data show that BAFF expression is 
increased in male COVID-19 patients, which may worsen the condition. 
Admittedly, there remain certain shortages in our systematic review. First of all, 
only thirty-nine studies were incorporated which focused on the morbidity, severity 
and mortality of COVID-19 infection. These studies are mostly from China. Up to 
March 28, 2020, more than 600,000 cases have been reported worldwide. Most of 
aforementioned cases have not been covered and published in the available studies. 
With an intensified body of case studies being reported, more large population and 
superior quality studies could be embedded to consolidate our findings. Secondly, our 
systematic review was consisted of 39 individual studies with various contexts, which 
may induce insufficient statistical availability and dispersive results to a lesser extent. 
Third, in rare cases, there is no way to determine which reports are repeated. there 
may be some overlap in patients among different studies, especially most of the 
included Chinese studies were summarized in the national report.7 However, in the 
sensitivity analysis, the results were still consistent after omitting the Chinese national 
report in the analysis (Figure 4A). As for the heterogeneity of gender composition 
analysis, it may be attributed to a different baseline ratio of male and female in each 
region. 
There may be sex differences in the susceptibility and diseases progression of 
patients with COVID-19. The clinical symptoms of male are more serious than those 
of women, and the outcome of hospitalization is less favorable. From the results of 
integrated bioinformatic analyses, it can be postulated that androgen deprivation 
therapy, frequently adopted in the treatment of prostate cancer, could potentially exert 
a protective and therapeutic effect against the coronavirus. Nevertheless, the findings 
of the study should be interpreted with caution. Large population-based studies are 
needed to verify these findings. 
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Figure Legends 
Figure 1. Flow diagram of the study selection process. 
Figure 2. Visualization of pooled analyses of morbidity, severity, age subgroup 
severity and mortality. (A) An albatross plot of the morbidity. (B) A forest plot of 
severity. (C) A forest plot of severity with age subgroup analysis. (D) A forest plot of 
mortality. 
Figure 3. Single-cell transcriptomic profiling of human lung tissue samples. (A) t-
SNE view of combined adult human lung tissue samples from 2 male and 6 female 
donors. Color coded by re-evaluated clusters. (B) Comparison of percentages of 
different cell types between lung tissue samples of male and female origins. (C) 
Feature plot showing the expression level of ACE2. (D) ACE2 co-expression network 
in lung tissues of male origin. 
Figure 4. Sex-based differences in gene expression, pathway enrichment and cell-
cell communications. (A) Volcano plot showing differentially expressed genes 
between male and female lung tissue samples. (B) Visualization of enriched 
pathways. (C) Bubble plot visualization of differentially expressed cytokines in 
ACE2-expressing cell populations. 
Figure 5. Co-expression analysis of AR, ACE2 and TMPRSS2. (A) Single-cell 
RNAseq data of adult lung tissues showing a positive correlation between ACE2 and 
TMPRSS2 expression pattern. (B) Heatmap showing the correlation between AR and 
ACE2/TMPRSS2 in multiple cancer types across the TCGA PANCAN cohort. (C)(D) 
Changes in expression after chemical (C) or surgical (D) castration. r, Pearson 
correlation coefficient. N3, Prostate from sham-treated mouse. C3, Prostate, 3 days 
after castration. C14, Prostate, 14 days after castration. C14+T3, Prostate, 3 days after 
testosterone treatment of C14. 
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Table 1 Characteristics of all patients with COVID-19 included in the meta-analysis
Author Date Deadline Area Average Age Total Patients Male Female Severe smoking Death Comorbidities Research Type Quality Reference
Qian G 3/17 2/21 China,Zhejiang 50(5-96) 91 37 54 9 \ 0 23 Retrospective Research 17 28
Livingston E 3/17 3/1 Italy 64 22512 13462 9050 6731 \ 1625 \ Report 7 6
Wang Y 3/17 2/23 China,Shenzhen 49(2-69) 55 22 23 2 \ 0 8 Descriptive Research 14 29
KSID 3/16 3/2 Korea 20-50 4212 1591 2621 \ \ 22 \ Report 15 13
Su YJ 3/14 2/11 China,Taiwan 56.6 10 7 3 \ \ \ \ Retrospective Research 11 30
Dong X 3/13 \ China,Tianjin 48.62(16.83) 135 72 63 \ \ 3 \ Descriptive Research 17 31
Mizumoto K 3/12 2/20 Japan \ 634 321 313 \ \ \ \ Descriptive Research 16 47
Deng L 3/11 2/13 China,Zhuhai \ 33 17 16 \ \ \ 19 Retrospective Research 16 32
Zhou F 3/11 1/31 China,Wuhan 56(46-67) 191 119 72 119 11 54 91 Retrospective Research 15 10
Wu Y 3/10 2/2 China, Wuhan \ 297 147 150 83 \ 17 \ Retrospective Research 16 33
Gao Q 3/10 2/14 China, Wuhan 48 ( 35-58.5) 213 108 105 33 \ 7 19 Retrospective Research 14 34
Chen X 3/6 2/14 China, Hubei 46.0 (34.0-59.0) 291 145 146 50 \ 2 93 Observational Research 16 35
Zhang G 3/6 2/10 China, Wuhan 55.0(39.0-66.5) 221 108 113 55 \ 12 78 Retrospective Research 17 36
Wu W 3/6 2/6 China, Guangdong 43.1(17.1) 21 10 11 7 \ \ \ Retrospective Research 17 37
Nicholas E 3/6 2/27 UK  42.5( 0.5-76) 68 32 36 \ \ \ \  Descriptive Research 12 38
Cao M 3/6 2/25 China,Shanghai 50.1 (16.3) 198 101 97 19 11 1 69 Retrospective Research 17 39
Zhao W 3/3 \ China, Hunan 44.44 (12.3) 101 56 45 14 \ \ 30 Retrospective Research 14 40
Young B 3/3 2/3 Singapore 47(31-73) 18 9 9 7 \ \ 5 Descriptive Research 12 41
Xiao F 3/3 2/14 China,Zhuhai 43(0.83-78) 73 41 32 4 9 \ 7 Retrospective Research 12 42
Qi D 3/3 2/16 China, Chongqing 48.0(20-80) 267 149 118 50 53 4 41 Retrospective and Descriptive Research 17 43
Wang Y 3/3 2/10 China, Wuhan \ 110 48 62 38 26 \ 51 Retrospective Research 16 44
Chen X 3/3 2/27 China, Wuhan 64.6(18.1) 48 37 11 27 \ 3 \ Retrospective Research 15 45
Cheng J 3/2 1/2 China, Henan 46(36-59) 1079 573 505 72 \ 11 \ Descriptive Research 16 46
Wu J 2/29 2/14 China,Jiangsu 46.1(15.42) 80 39 41 3 \ 0 38 Descriptive Research 16 48
Li K 2/29 2月 China, Chongqing 45.5(12.3) 83 44 39 25 \ \ 15 Retrospective Research 17 49
Li J 2/29 2/11 China, Wuhan 62.0 (51.0-70.0) 47 28 19 47 \ 1 30 Retrospective Research 16 50
Guan W 2/28 1/29 China 47(35-58) 1099 637 459 173 261 15 261 Retrospective Research 15 8
Tian S 2/27 1/30 China,Beijing 47.5(1-94) 262 127 135 46 \ 3 \ Retrospective Research 17 51
Liu Y 2/27 2/1 China, Wuhan 55 (43-66) 109 59 50 53 \ 31 76 Retrospective Research 17 52
Xu Y 2/25 2月 China, Beijing 43.9(16.8) 50 29 21 13 \ \ \ Retrospective Research 14 53
Cao W 2/25 2/20 China,Xiangyang \ 128 60 68 21 \ \ \ Retrospective Research 15 54
Yang X 2/24 1/26 China, Wuhan 59.7 (13.3) 52 35 17 52 32 21 Retrospective Research 16 55
Liu L 2/23 2/3 China, Chongqing 45(34-51） 51 32 19 7 \ 1 10 Retrospective Research 16 56
Liu J 2/22 1/24 China, Wuhan 48.7(13.9) 40 15 25 13 \ \ 14 Retrospective Research 16 57
Zhang J 2/19 3/2 China,wuhan 57（25-87） 140 71 69 58 9 \ 90 Retrospective Research 15 58
Xu X 2/19 1/26 China, Zhejiang 41（32-52） 62 36 26 \ \ 0 20 Retrospective Research 15 59
CDC 2/17 2/11 China 30-69 44672 22981 21691 8255 \ 1023 5276 Descriptive Research 15 7
Huang C 2/15 1/2 China, Wuhan 49(41–58) 41 30 11 13 3 6 13 Retrospective Research 16 60
Wang D 2/7 1/28 China, Wuhan 56(42-68) 138 75 63 36 \ 6 64 Retrospective Research 17 5
 
Table 2. Gender differences in the composition of patients with COVID-19 
 
Author 
Dat
e 
Area 
Total 
Patients 
Male Female Reference 
Qian GQ 3/17 China,Zhejiang 91 37 54 28 
Livingston E 3/17 Italy 22512 13462 9050 6 
Wang Y 3/17 China,Shenzhen 55 22 23 29 
KSID 3/16 Korea 4212 1591 2621 13 
Su Y 3/14 China,Taiwan 10 7 3 30 
Dong X 3/13 China,Tianjin 135 72 63 31 
Deng L 3/11 China,Zhuhai 33 17 16 32 
Zhou F 3/11 China,Wuhan 191 119 72 10 
Wu Y 3/10 China, Wuhan 297 147 150 33 
Gao Q 3/10 China, Wuhan 213 108 105 34 
Chen X 3/6 China, Hubei 291 145 146 35 
Zhang G 3/6 China, Wuhan 221 108 113 36 
Wu W 3/6 China, Guangdong 21 10 11 37 
Nicholas E 3/6 UK 68 32 36 38 
Cao M 3/6 China,Shanghai 198 101 97 39 
Zhao W 3/3 China, Hunan 101 56 45 40 
Young B 3/3 Singapore 18 9 9 41 
Xiao F 3/3 China,Zhuhai 73 41 32 42 
Qi D 3/3 China, Chongqing 267 149 118 43 
Wang Y 3/3 China, Wuhan 110 48 62 44 
Chen X 3/3 China, Wuhan 48 37 11 45 
Cheng J 3/2 China, Henan 1079 573 505 46 
Mizumoto K 3/1 Japan 634 321 313 47 
Wu J 2/29 China,Jiangsu 80 39 41 48 
Li K 2/29 China, Chongqing 83 44 39 49 
Li J 2/29 China, Wuhan 47 28 19 50 
Guan W 2/28 China 1099 637 459 8 
Tian S 2/27 China,Beijing 262 127 135 51 
Liu Y 2/27 China, Wuhan 109 59 50 52 
Xu Y 2/25 China, Beijing 50 29 21 53 
Cao W 2/25 China,Xiangyang 128 60 68 54 
Yang X 2/24 China, Wuhan 52 35 17 55 
Liu L 2/23 China, Chongqing 51 32 19 56 
Liu J 2/22 China, Wuhan 40 15 25 57 
Zhang J 2/19 China,wuhan 140 71 69 58 
Xu X 2/19 China, Zhejiang 62 36 26 59 
CDC 2/17 China 44672 22981 21691 7 
Huang C 2/15 China, Wuhan 41 30 11 60 
Wang D 2/7 China, Wuhan 138 75 63 5 
Table 3. Comparison of severe cases between male and female patients with 
COVID-19 
 
Author Date Male 
Male 
Severe 
Female 
Female 
Severe 
P Value Reference 
Wu Y 3/10 147 45 150 38 \ 33 
Gao Q 3/10 108 22 105 11 \ 34 
Chen X 3/6 145 27 146 23 0.629 35 
Zhang G 3/6 108 35 113 20 0.011 36 
Wu W 3/6 10 4 11 3 0.038 37 
Cao M 3/6 101 17 97 2 ＜0.001 39 
Qi D 3/3 149 39 118 11 <0.001 43 
Wang Y 3/3 48 24 62 14 0.004 44 
Chen X 3/3 37 24 11 3 <0.001 45 
Zhao W 3/1 56 8 45 6 0.89 40 
Li K 2/29 44 15 39 10 0.402 49 
Guan W 2/28 637 100 459 73 \ 8 
Tian S 2/27 127 26 135 20 0.23 51 
Liu Y 2/27 59 28 50 25 0.79 52 
Xu Y 2/25 29 7 21 6 \ 53 
Cao W 2/25 60 12 68 9 >0.05 54 
Liu L 2/23 32 3 19 4 0.109 56 
Liu J 2/22 15 7 25 6 0.138 57 
Zhang J 2/19 71 33 69 25 0.219 58 
Huang C 2/15 30 11 11 2 0.24 60 
Wang D 2/7 75 22 63 14 0.34 5 
*Severe group in our study included ICU cases, severe case and critical cases. 
 
 
  
Table 4. Comparison of mortality between male and female patients with 
COVID-19 
 
Author Date Male 
Male 
Died 
Female 
Female 
Died 
P Value Reference 
KIDS 3/16 1591 13 2621 9 \ 13 
Zhou F 3/11 119 38 72 16 0.15 10 
Wu Y 3/10 147 13 150 4 \ 33 
Gao Q 3/10 108 5 105 2 \ 34 
Zhang G 3/6 108 7 113 2 0.681 36 
Cheng J 3/2 573 7 505 4 \ 46 
Yang X 2/24 35 21 17 11 \ 55 
CDC 2/17 22981 653 21691 370 \ 7 
 
Supplementary Figure Legends 
Figure S1. Funnel plots for different outcomes. Funnel plots for (A) male/female 
ratio, (2) odds ratio of severe cases, and (3) odds ratio of mortality. 
Figure S2. Bar charts representing cell-cell communications. Intercellular 
communications between ACE2-expressing AT2 cells with other types of cells, with the 
ACE2 molecule functioning as (A) a receptor, and (B) a ligand. 
Figure S3. Single-cell transcriptomic profiling of normal prostate tissue samples. 
(A) (B) scRNA-seq of normal prostate tissues from 3 healthy young donors 
(GSE117403). (A) Left, UMAP clustering of combined normal prostate tissue samples. 
Middle, feature plot showing ACE2 expression level of individual cells. Right, violin 
box plot showing the expression level of ACE2 among different cell populations. (B) 
Bar chart showing the percentage of ACE-positive cells in different epithelial cell 
clusters. (C) scRNA-seq of normal prostate tissues from 15 healthy donors aged 17-42 
(GUDMAP 16-WPBW). Left, UMAP clustering of combined normal prostate tissue 
samples. Middle, feature plot showing ACE2 expression level of individual cells. Right, 
violin box plot showing the expression level of ACE2 among different cell populations. 
Figure S4. Single-cell transcriptomic profiling of testis tissue samples. Clustering 
and ACE2 expression level of single testicular cells in  (A) young adults, (B) 
spermatogonial stem cells, and (C) men during puberty. Left, clustering maps. Right, 
Feature maps showing ACE2 expression level of individual cells. SSCs, spermatogonial 
stem cells. 
Figure S5. Genome browser view of AR ChIP-seq and H3K27ac ChIP-seq tracks 
at the ACE2 locus in the C4-2B cell line. 
Figure S6. Genome browser view of AR ChIP-seq, H3K27ac ChIP-seq, H3K4me1 
ChIP-seq, and ATAC-seq tracks at the ACE2 locus in the LNCaP cell line. 
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Table S1. Risk of bias and methodological quality of the included studies
Introduction
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20
Author reference 1.Were the aims/objectives of the study clear?2.Was the study d sign appropriate for the stated aim(s)?3.Was the sampl  size justified?4.Was the target/ref renc  population clearly defined? (Is it clear who the research was5.Was ample frame taken from an appropriate population base so th t it closely6.Was the selectio process likely to sel ct subjects/participants hat were representative7.Wer  measures undertak n to addres  and ategorise n n-respond rs?8.W re the ri k fact r an outcom v riables measu d app opriate to the aims of the9.Wer  he risk factor and ou come variables m a ured correctly using instruments/measurements that had been trialled, piloted or published previously?10.Is it cle r wh t a  used to d termined statistical sign fica c  and/or preci ion estimates? (eg, p values, CIs)11.Were  th s (i cluding sta isti al meth ds) s fficiently de c ib d to en bl  them12.W  the basic ata dequately described?13.Does th respon e rate rai conc ns abo t non-respons  bias?14.If appropriate, was information about n n-respond rs d cribed?15.Were the result nternally con istent?16.Were the esults f r th analyse  in the method , presented?17.Discussio18.Were th  limit tions of the study discussed?19.W re there any fun ing o rc s or conflicts of interest that may affect the authors’interpretation of the results?20.Was e hical approval sent f participants att ined?Toal s ore
Qian G 28 Yes Yes Yes Yes Yes Yes ？ Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes No Yes 17
Livingston E 6 Yes Yes Yes Yes ? ? ？ ? ? No ? No No No Yes No ? Yes ? ? 7
Wang Y 29 Yes Yes Yes Yes Yes Yes ？ Yes Yes No Yes Yes No Yes ? Yes ? Yes No Yes 14
KSID 13 Yes Yes Yes Yes Yes Yes ？ Yes Yes No Yes Yes Yes No ? Yes Yes Yes ? Yes 15
Su YJ 30 Yes Yes Yes Yes Yes Yes ？ No No No Yes Yes No Yes Yes No ? ? No Yes 11
Dong X 31 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Mizumoto K 47 Yes Yes Yes Yes Yes Yes ？ Yes Yes No Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Deng L 32 Yes Yes Yes Yes Yes Yes ？ ? Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Zhou F 10 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No ? Yes Yes ? Yes No Yes 15
Wu Y 33 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No No Yes Yes Yes Yes No Yes 16
Gao Q 34 Yes Yes Yes Yes Yes Yes ？ Yes No No Yes Yes No Yes Yes ？ Yes Yes No Yes 14
Chen X 35 Yes Yes Yes Yes Yes Yes ？ No Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Zhang G 36 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Wu W 37 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Nicholas E 38 Yes Yes Yes ？ Yes Yes ？ No No No Yes Yes No Yes ？ Yes Yes Yes No Yes 12
Cao M 39 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Zhao W 40 Yes Yes Yes Yes Yes Yes ？ ？ ？ Yes Yes Yes No Yes Yes ？ Yes Yes No Yes 14
Young B 41 Yes Yes Yes Yes Yes Yes ？ ？ ？ NO Yes Yes No No Yes Yes ? Yes No Yes 12
Xiao F 42 Yes Yes Yes Yes Yes Yes ？ ？ ？ NO Yes Yes No No Yes Yes ? Yes No Yes 12
Qi D 43 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Wang Y 44 Yes Yes Yes Yes Yes Yes ？ Yes ？ Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Chen X 45 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes No ? No Yes 15
Cheng J 46 Yes Yes No Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Wu J 48 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes No Yes No Yes 16
Li K 49 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Li J 50 Yes Yes Yes Yes Yes Yes ？ No Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Guan W 8 Yes Yes No Yes Yes Yes ？ No Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 15
Tian S 51 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Liu Y 52 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Xu Y 53 Yes Yes Yes Yes ? Yes ？ Yes Yes No Yes Yes No Yes Yes Yes Yes Yes No ？ 14
Cao W 54 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No ？ Yes Yes Yes ？ No Yes 15
Yang X 55 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No ？ Yes Yes Yes Yes No Yes 16
Liu L 56 Yes Yes Yes Yes ? Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Liu J 57 Yes Yes Yes Yes ? Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Zhang J 58 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No ？ Yes Yes Yes No No Yes 15
Xu X 59 Yes Yes Yes Yes ? Yes ？ Yes Yes Yes Yes Yes No ？ Yes Yes Yes Yes No Yes 15
CDC 7 Yes Yes Yes Yes ? Yes ？ Yes ? Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 15
Huang C 60 Yes Yes Yes Yes Yes Yes ？ ? Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 16
Wang D 5 Yes Yes Yes Yes Yes Yes ？ Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes 17
Methods Results Discussion Other
Coef. Std. Err. t P> |t|    95% CI
Morbidity -0.2573771 0.9040747 -0.28 0.777 -2.089206 1.574452
Severity 1.259753 0.6167905 2.04 0.055 -0.0312042 2.550711
Mortality 0.358895 0.3756831 0.96 0.376 -0.5603686 1.278159
Table S3. Sensitivity analysis of the severity for 21 included studies
Author Date  Estimate OR 
Wu Y 3/10 1.6678668 1.291166 2.1544712
Gao Q 3/10 1.6009253 1.252503 2.0462716
Chen X 3/6 1.6682906 1.29682 2.1461678
Zhang G 3/6 1.5895121 1.243146 2.0323834
Wu W 3/6 1.6275051 1.277919 2.0727232
Cao M 3/6 1.5475454 1.245357 1.9230609
Qi D 3/3 1.5309649 1.220754 1.9200046
Wang Y 3/3 1.5507388 1.23053 1.9542725
Chen X 3/3 1.5827113 1.253737 1.9980072
Zhao W 3/1 1.6524721 1.294761 2.10901
Li K 2/29 1.637333 1.279081 2.095926
Guan W 2/28 1.7173474 1.362389 2.1647866
Tian S 2/27 1.6450169 1.277818 2.1177359
Liu Y 2/27 1.6843767 1.32092 2.1478407
Xu Y 2/25 1.6603048 1.305324 2.1118217
Cao W 2/25 1.6307118 1.274032 2.0872478
Liu L 2/23 1.6617414 1.317398 2.0960901
Liu J 2/22 1.6055609 1.262431 2.0419543
Zhang J 2/19 1.6403354 1.275406 2.1096814
Huang C 2/15 1.6150899 1.269645 2.0545242
Wang D 2/7 1.6432891 1.280324 2.1091533
1.6256158 1.28406 2.0580247
Table S4. Sensitivity analysis of the mortality for 8 included studies
Author Date  Estimate OR 
KIDS 3/16 1.6962082 1.498673 1.9197793
Zhou F 3/11 1.7105864 1.510205 1.9375559
Wu Y 3/10 1.6939224 1.49752 1.916083
Gao Q 3/10 1.704739 1.507646 1.927598
Zhang G 3/6 1.700071 1.503474 1.9223759
Cheng J 3/2 1.7099531 1.511843 1.9340236
Yang X 2/24 1.7215263 1.522026 1.9471766
CDC 2/17 1.939573 1.307478 2.8772526
1.7082885 1.51129 1.9309661Combined
Table S2. Egger's regression test of each analysis.
95% CI
Combined
95% CI
